scieee Open visual document viewer

A case-control analysis of the impact of venous thromboembolic disease on quality of life of patients with cancer: Quality of life in cancer (QCA) study

Marin-Barrera, Lucia; Muñoz-Martin, Andres J.; Rios Herranz, Eduardo; Garcia-Escobar, Ignacio; Beato, Carmen; Otero, Remedios; Jara-Palomares, Luis

Abstract

Abstract: Although there is published research on the impact of venous thromboembolism (VTE) on quality of life (QoL), this issue has not been thoroughly investigated in patients with cancer—particularly using specific questionnaires. We aimed to examine the impact of acute symptomatic VTE on QoL of patients with malignancies. This was a multicenter, prospective, case-control study conducted in patients with cancer either with (cases) or without (controls) acute symptomatic VTE. Participants completed the EORTC QLQ-C30, EQ-5D-3L, PEmb-QoL, and VEINES-QOL/Sym questionnaires. Statistically significant and clinically relevant differences in terms of global health status were examined. Between 2015 and 2018, we enrolled 425 patients (128 cases and 297 controls; mean age: 60.2 ± 18.4 years). The most common malignancies were gastrointestinal (23.5%) and lung (19.8%) tumors. We found minimally important differences in global health status on the EQ-5D-3L (cases versus controls: 0.55 versus 0.77; mean difference: −0.22) and EORTC QLQ-C30 (47.7 versus 58.4; mean difference: −10.3) questionnaires. There were minimally important differences on the PEmb-QoL questionnaire (44.4 versus 23; mean difference: −21.4) and a significantly worse QoL on the VEINES-QOL/Sym questionnaire (42.7 versus 51.7; mean difference: −9). In conclusion, we showed that acute symptomatic VTE adversely affects the QoL of patients with malignancies.

Full text

cance s A icle A Case-Con ol Analysis o he Impac o Venous Th omboembolic Disease on Quali y o Li e o Pa ien s wi h Cance : Quali y o Li e in Cance (Qca) S udy Lucia Ma in-Ba e a 1, And es J. Muñoz-Ma in 2, Edua do Rios-He anz 3, Ignacio Ga cia-Escoba 4, Ca men Bea o 5, Ca me Fon 6, Es e ania Oncala-Sibajas 7, Al onso Re uel a-Rod iguez 8, Ma ia Ca men A eses 9, Vic o Ri as-Jimenez 10, Ma ia Angeles Mo eno-San os 11, Ai o Ballaz-Quincoces 12, Juan-Bosco Lopez-Saez 13, I ia Gallego 2, Te esa Elias-He nandez 1, Ma ia Isabel Asensio-C uz 1, Ley e Chasco-Eguilaz 12, Gonzalo Ga cia-Gonzalez 2, Pu i icacion Es e ez-Ga cia 14, Remedios O e o 1, Jo ge Lima-Al a ez 15 and Luis Ja a-Paloma es 1,* 1 Respi a o y Depa men , Medical Su gical Uni o Respi a o y Diseases, Hospi al Vi gen del Rocio, CIBERES, 41013 Se illa, Spain; [email p o ec ed] (L.M.-B.); [email p o ec ed] (T.E.-H.); [email p o ec ed] (M.I.A.-C.); o e o@sepa .es (R.O.) 2Medical Oncology Depa men , Hospi al Gene al Uni e si a io G ego io Ma añón, 28009 Mad id, Spain; [email p o ec ed] (A.J.M.-M.); [email p o ec ed] (I.G.); [email p o ec ed] (G.G.-G.) 3Hema ology and Hemo he apy Depa men , Hospi al Uni e si a io Vi gen de Valme, 41701 Se illa, Spain; [email p o ec ed] 4Medical Oncology Depa men , HGU de Ciudad Real, 13003 Ciudad Real, Spain; [email p o ec ed] 5Medical Oncology Depa men , Hospi al Uni e si a io Vi gen Maca ena, 41009 Se illa, Spain; [email p o ec ed] 6 Medical Oncology Depa men , DIBAPS/T ansla ional Genomics and Ta ge ed The apeu ics in Solid Tumo s, Hospi al Clínic, 08036 Ba celona, Spain; [email p o ec ed] 7Eme gency Depa men , Hospi al Vi gen Maca ena, 41009 Se illa, Spain; [email p o ec ed] 8Medical Oncology Depa men , Hospi al Uni e si a io Cen al de As u ias, 33611 O iedo, Spain; [email p o ec ed] 9Medical Oncology Depa men , Hospi al de O ense, 32616 O ense, Spain; ka melea [email p o ec ed] 10 Medical Oncology Depa men , Hospi al de Je ez de la F on e a, 11407 Cádiz, Spain; [email p o ec ed] 11 Medical Oncology Depa men , H. U. Pue o Real, 11510 Cádiz, Spain; [email p o ec ed] 12 Respi a o y Depa men , Hospi al de Galdakao-Usansolo, 48960 Bizkaia, Spain; ai o [email p o ec ed] (A.B.-Q.); [email p o ec ed] (L.C.-E.) 13 In e nal Medicine Uni . H. U. Pue o Real, 11510 Cádiz, Spain; [email p o ec ed] 14 Medical Oncology Depa men , Hospi al Vi gen del Rocio, 41013 Se illa, Spain; [email p o ec ed] 15 Respi a o y Depa men , Hospi al Uni e si a io Vi gen de Valme, 41701 Se illa, Spain; [email p o ec ed] *Co espondence: [email p o ec ed]; Tel.: +34-6-67-95-64-80; Fax: +34-9-55-01-21-90 Recei ed: 4 Decembe 2019; Accep ed: 24 Decembe 2019; Published: 26 Decembe 2019   Abs ac : Al hough he e is published esea ch on he impac o enous h omboembolism (VTE) on quali y o li e (QoL), his issue has no been ho oughly in es iga ed in pa ien s wi h cance —pa icula ly using speci ic ques ionnai es. We aimed o examine he impac o acu e symp oma ic VTE on QoL o pa ien s wi h malignancies. This was a mul icen e , p ospec i e, case-con ol s udy conduc ed in pa ien s wi h cance ei he wi h (cases) o wi hou (con ols) acu e symp oma ic VTE. Pa icipan s comple ed he EORTC QLQ-C30, EQ-5D-3L, PEmb-QoL, and VEINES-QOL/Sym ques ionnai es. S a is ically signi ican and clinically ele an di e ences in e ms o global heal h s a us we e examined. Be ween 2015 and 2018, we en olled 425 pa ien s (128 cases Cance s 2020,12, 75; doi:10.3390/cance s12010075 www.mdpi.com/jou nal/cance s Cance s 2020,12, 75 2 o 12 and 297 con ols; mean age: 60.2 ± 18.4 yea s). The mos common malignancies we e gas oin es inal (23.5%) and lung (19.8%) umo s. We ound minimally impo an di e ences in global heal h s a us on he EQ-5D-3L (cases e sus con ols: 0.55 e sus 0.77; mean di e ence: − 0.22) and EORTC QLQ-C30 (47.7 e sus 58.4; mean di e ence: − 10.3) ques ionnai es. The e we e minimally impo an di e ences on he PEmb-QoL ques ionnai e (44.4 e sus 23; mean di e ence: − 21.4) and a signi ican ly wo se QoL on he VEINES-QOL/Sym ques ionnai e (42.7 e sus 51.7; mean di e ence: − 9). In conclusion, we showed ha acu e symp oma ic VTE ad e sely a ec s he QoL o pa ien s wi h malignancies. Keywo ds: neoplasm; quali y o li e; enous h omboembolism; pulmona y embolism; enous h ombosis 1. In oduc ion Venous h omboembolic disease (VTE) consis s o pulmona y embolism (PE) and deep ein h ombosis (DVT). In he gene al popula ion, PE anks hi d among all causes o ca dio ascula mo ali y— ollowing myoca dial in a c ion and s oke [ 1 ]. The bu den o his condi ion is e en highe in pa ien s wi h malignancies [ 2 ]. Pa ien s wi h umo s also p esen a ma kedly inc eased isk (up o a ou - old) o VTE han hose wi hou . Con e sely, app oxima ely 20% o pa ien s wi h VTE ha e an ac i e malignancy [ 3 ], which in u n po ends a highe isk o complica ions (i.e., bleeding, ecu en VTE, and dea h) [4–7]. Heal h- ela ed quali y o li e (QoL)—de ined as he pe cep ion a pa ien has o he e ec s o a disease o i s ea men on dis inc domains, including physical, emo ional, and social well-being [ 8 ]—has ecen ly become a subjec o in ense in es iga ion. Se e al gene ic ques ionnai es aimed a assessing QoL in e e yday clinical p ac ice ha e been de eloped. Howe e , disease-speci ic ques ionnai es a e gene ally mo e sensi i e in he de ec ion o sub le QoL changes in selec ed clinical popula ions. Di e en ques ionnai es a e cu en ly a ailable o he speci ic assessmen o QoL in pa ien s wi h VTE. The Venous Insu iciency Epidemiological and Economic S udy-Quali y o Li e/Symp oms (VEINES-QOL/Sym) [ 9 , 10 ] and he Pulmona y Embolism Quali y o Li e ques ionnai e (PEmb-QoL) [11,12] ha e been designed o pa ien s wi h DVT and PE, espec i ely. Al hough he e is published esea ch on he impac o DVT [ 13 ] and PE [ 14 ] on QoL, his issue has no been ho oughly in es iga ed in pa ien s wi h cance [ 15 ] and, pa icula ly, using speci ic ques ionnai es. We he e o e designed he Quali y o li e in Cance (QCa) s udy o examine he impac o acu e symp oma ic VTE on QoL o pa ien s wi h malignancies. 2. Me hods 2.1. S udy Design The QCa s udy is a mul icen e , p ospec i e, case-con ol in es iga ion conduc ed in pa ien s wi h malignancies. Rec ui men was conduc ed be ween June 2015 and Janua y 2018 in he ou pa ien acili ies o 13 Spanish hospi als. The s udy in es iga o s we e in specialis s in oncology, hema ology, in e nal medicine, and espi a o y medicine. Pa ien s wi h cance ei he wi h (cases) o wi hou (con ols) acu e symp oma ic VTE we e included. Con ols we e deemed eligible a any ime du ing he cou se o hei disease and we e equi ed o comple e he QoL ques ionnai es a inclusion. Cases we e included in he s udy a he ime o acu e symp oma ic VTE, and quali y o li e we e illed 30 days a e he index h ombo ic e en (30 ± 2 days). All ques ionnai es we e comple ed a he same ime poin o a oid a sou ce o po en ial con ounding. All clinical da a and esponse o ques ionnai es we e sepa a ed om pe sonal in o ma ion and analysed in an anonymized ashion. The s udy p o ocol was e iewed and app o ed by he Resea ch E hics Commi ee o he Vi gen del Rocio Hospi al, Se illa, Spain (code: 0191-N-14) and subsequen ly a i ied by each pa icipa ing cen e . All pa ien s p o ided Cance s 2020,12, 75 3 o 12 w i en in o med consen be o e inclusion. The comple e p o ocol has been p e iously desc ibed in de ail [16]. The main esea ch o he s udy was o in es iga e he impac o acu e symp oma ic VTE on QoL o pa ien s wi h malignancies. Wi h his aim, we compa ed he global heal h s a us o cases and con ols using ou QoL ques ionnai es. Seconda y endpoin s included he compa isons o di e en QoL dimensions and h ee subg oup analyses (PE e sus DVT, men e sus women, analysis acco ding o umo si e). The ollowing ques ionnai es we e used: (1) Eu opean O ganiza ion o Resea ch and T ea men o Cance quali y o li e ques ionnai e (EORTC QLQ-C30) e sion 3.0 [ 17 ], which is designed o assess QoL in pa ien s wi h cance ; (2) he gene ic EQ-5D-3L ques ionnai e [ 18 ]; (3) he PEmb-QoL ques ionnai e, which is speci ic o pa ien s wi h PE [ 11 ], and (4) he VEINES-QOL/Sym ques ionnai e [ 9 , 10 ], which examines speci ic symp oms o DVT and ocuses on limi a ions o daily li ing ac i i ies. The EQ-5D-3L ques ionnai e is a commonly used gene ic heal h ques ionnai e capable o compa ing di e en diseases [ 18 ]. I allows he calcula ion o a u ili y index (UI), which comp ises i e di e en dimensions (mobili y, sel -ca e, daily ac i i ies, pain/discom o , and anxie y/dep ession) [ 18 ] which a e sco ed om 1 (no p oblems) o 5 (unable o/ex eme p oblems). The esponses a e combined o ob ain a 5-digi numbe ( om 11, 111 o 55555) ha summa izes he pa ien ’s heal h s a us. This alue is subsequen ly con e ed in o he UI, which may ange om 0.208 (wo s possible heal h) o 1.000 (bes possible heal h). The minimally impo an di e ence (MID) on he EQ-5D ques ionnai e o pa ien s wi h malignancies is 0.06−0.08 UI [19]. The EORTC QLQ-C30 ques ionnai e, which has been speci ically designed o pa ien s wi h malignancies, comp ises i e unc ioning scales (physical, social, ole, cogni i e, and emo ional unc ioning), h ee symp om scales ( a igue, pain, and nausea/ omi ing), one global heal h scale, and six independen i ems (dyspnea, sleep dis u bances, ano exia, cons ipa ion, dia hea, and economic impac ). High sco es on he global heal h scale and unc ioning s a us e lec a be e QoL, whe eas high alues in he symp oms scale indica e a educ ion in QoL (owing o he p esence o cance -associa ed symp oms) [ 20 – 22 ]. The index sco e anges om 0 (dea h) o 1 ( ull heal h), wi h highe sco es ( om 0.654 o 1) e lec ing a be e heal h s a us. The MID on he EORTC QLQ-C30 ques ionnai e a ies om 6 o 15 poin s [23–25]. The PEmb-QoL ques ionnai e—a disease-speci ic ques ionnai e o pa ien s wi h PE [ 11 ]—has six di e en dimensions ( equency o complain s, limi a ions in daily li e ac i i ies, wo k- ela ed p oblems, social limi a ions, in ensi y o complain s, and emo ional complain s). Highe sco es e lec a lowe QoL and he minimally clinically impo an di e ence (MCID) is 15 poin s [ 26 ]. The VEINES-QOL/Sym ques ionnai e [ 9 , 10 ], which akes in o accoun he symp oms, limi a ions, and daily li e ac i i ies o he las ou weeks, p o ides he VEINES-QOL sco e (which e lec s QoL) and he VEINES/Sym sco e (which p o ides a quan i a i e measu e o symp oms). Highe sco es e lec a be e QoL. 2.2. Sample Size Calcula ion The planned case-con ol a io was 1:2. To achie e a powe o 80% o de ec di e ences (in con as o he null hypo hesis) using a wo independen -sample S uden ’s - es wi h an alpha e o o 0.05, unde he assump ions o a mean in he con ol g oup o 55.75 uni s, a mean in he case g oup o 45.26 uni s, and a s anda d de ia ion in bo h g oups o 26.05 uni s, a o al o 98 cases and 196 con ols we e equi ed ( o aling 294 subjec s). Unde he hypo hesis o a 5% d opou a e, we planned o ec ui a minimum o 104 cases and 208 con ols ( o aling 312 subjec s). 2.3. S a is ical Analysis Fo each ques ionnai e, he dis ibu ions o sco es, means, medians, and he pe cen age o esponden s wi h minimum/maximum sco es (indica ing loo ing and ceiling e ec s) a e p esen ed. The c i e ia o accep abili y o each ques ionnai e we e as ollows: (1) less han 10% missing da a o summa y sco es, (2) e en dis ibu ion o endo semen equencies ac oss esponse ca ego ies, Cance s 2020,12, 75 4 o 12 and (3) less han 10% loo and ceiling e ec s o summa y sco es. We applied he ela i e e iciency (RE) s a is ic and calcula ed he e ec size (Cohen’s d) o es ima e he ques ionnai e pe o mance (i.e., sensi i i y o de ec di e ences) in each s udy g oup. The RE s a is ic was de ined as he a io o F-s a is ics in he analysis o a iance (ANOVA) es s o he di e ences in sco es be ween known g oups [ 27 ]. Highe F-s a is ic alues indica e a g ea e e iciency o disc imina ion ( e sus he compa a o ). The e ec size was calcula ed using he di e ence in mean sco es di ided by he pooled s anda d de ia ion. The h eshold alues o e ec sizes we e de ined as small (0.2), mode a e (0.5), and la ge (0.8). Figu e 1p o ides a iolin plo . Violin plo s allow plo ing nume ical da a and can be ega ded as a combina ion be ween box plo s and ke nel densi y plo s. Ke nel densi y es ima ion (KDE) is a non-pa ame ic app oach o es ima e he p obabili y densi y unc ion o a andom a iable. Mo eo e , hese plo s show he ac ual dis ibu ion o he obse ed alues (do s in cases and iangles in con ols), ul ima ely allowing a ep esen a ion o he sco es used in he s udy. Boxplo s depic s he median (black line inside he box) and he in e qua ile ange ( he edges o he box). The ke nel densi y plo (g ey line) ep esen s he p obabili y densi y unc ion. La ge sec ions o he iolin plo indica e a highe p obabili y o obse a ion a a gi en alue, whe eas hinne sec ions co espond o a lowe p obabili y. S a is ical calcula ions we e pe o med using R ( e sion 3.5.3; Ma ch 11, 2019) and R S udio ( e sion 1.1.456) equipped wi h he dply ( e sion 0.8.3), e size ( e sion 0.7.4), PMCMR ( e sion 4.3), ca spec ( e sion 0.97), and ggplo 2 ( e sion 3.1.0) packages. The ull ep oducible code is p o ided in he Supplemen a y Ma e ials. 2.4. Da a Sha ing S a emen Fo o iginal da a, please con ac [email p o ec ed]. Indi idual pa icipan da a will no be sha ed. 3. Resul s The s udy sample consis ed o 425 pa ien s (128 cases and 297 con ols; mean age: 60.2 ±18.4 yea s; 58% men) (Table S1 include ec ui men pe cen e ). O hem, 77% we e ecei ing an icance ea men and 20% had a cen al enous ca he e . The mos common malignancies we e gas oin es inal (23.5%) and lung (19.8%) umo s. Dis an me as ases we e iden i ied in 68% o he s udy pa ien s, and he Eas e n Coope a i e Oncology G oup (ECOG) pe o mance s a us was 0–1 in 89% o he pa icipan s (Table 1). Adenoca cinoma was he mos equen his ology ype (58.8%). The dis ibu ion o VTE was as ollows: DVT (54.7%), PE (25%), and DVT plus PE (20.3%). The e we e no signi ican di e ences be ween he ime om cance diagnosis and he inclusion in he s udy be ween cases (14.76 ± 21.34 mon hs) and con ols (15.01 ± 25.57 mon hs). Mo e han hal o all cases (54.5%) and con ols (58.1%) we e included wi hin 6 mon hs om cance diagnosis. All cases ecei ed weigh -adjus ed low molecula weigh hepa in a inclusion. Table S2 shows he ma i al s a us, educa ion s a us, employmen s a us, and g oss income o he s udy pa icipan s. 3.1. Impac o Venous Th omboembolism on Quali y o Li e o Pa ien s wi h Malignancies The p esence o h ombosis in pa ien s wi h malignancies had a s a is ically signi ican and clinically ele an nega i e impac on he quali y o li e acco ding o he esul s o ou di e en ques ionnai es. O he 425 pa ien s included, 84% comple ed he EQ-5D ques ionnai e (n =355), 83% he EORTC QLQ-C30 ques ionnai e (n =354), 72% he Pemb-QOL ques ionnai e (n =306), and 72% he VEINES-QOL/Sym ques ionnai e (n =305). Cases and con ols di e ed signi ican ly in e ms o EQ-5D-3L esul s, and such di e ence was la ge han he MID (0.55 e sus 0.77, espec i ely; mean di e ence: − 0.22). Simila esul s we e ob ained on he EORTC QLQ-C30 ques ionnai e wi h ega d o he global heal h s a us (47.7 e sus 58.4, espec i ely; mean di e ence: − 10.3), physical unc ioning (64.4 e sus 80.6, espec i ely; mean di e ence: − 16.2), ole unc ioning (53.9 e sus 74.7, espec i ely; mean di e ence: − 20.8), and social unc ioning (62.2 e sus 74.1, espec i ely; mean di e ence: − 11.9). As a as symp oms a e conce ned, cases sco ed highe in e ms o a igue (48.4 e sus 33.7, espec i ely; Cance s 2020,12, 75 5 o 12 mean di e ence: +14.7), pain (36 e sus 23, espec i ely; mean di e ence: +13). and dyspnea (23.5 e sus 13, espec i ely; mean di e ence: +10.5; Table 2). Table 1. Clinical cha ac e is ics o he s udy pa ien s. Va iable Cases (Cance wi h VTE) Con ols (Cance wi hou VTE) En i e Coho Male sex, n (%) 65 (50.8%) 180 (60.8%) 245 (57.8%) Age, yea s (n =425); mean ±SD 63 (11.4) 59.1 (20.6) 60.2 (18.4) Body mass index, kg/m2(n =321), mean ±SD 27.2 (5.7) 26.1 (4.9) 26.4 (5.2) A e ial hype ension (n =392), n (%) 55 (44.0%) 88 (33.0%) 143 (36.5%) Dyslipidemia (n =391), n (%) 33 (26.6%) 58 (21.7%) 91 (23.3%) Diabe es melli us (n =392), n (%) 18 (14.4%) 43 (16.1%) 61 (15.6%) As hma (n =392), n (%) 3 (2.4%) 4 (1.5%) 7 (1.8%) Acu e co ona y synd ome (n =392), n (%) 3 (2.4%) 6 (2.2%) 9 (2.3%) S oke (n =392), n (%) 6 (4.8%) 7 (2.6%) 13 (3.3%) Smoking (n =392), n (%) 30 (24.0%) 61 (22.8%) 91 (23.2%) Non-s e oidal an i-in lamma o y d ugs (n =392), n (%) 12 (9.6%) 20 (7.5%) 32 (8.2%) S a ins (n =392), n (%) 22 (17.6%) 32 (12.0%) 54 (13.8%) Ac i e an icance ea men , n (%) 95 (75.4%) 203 (77.5%) 298 (76.8%) Cen al enous ca he e , n (%) 7 (5.6%) 70 (26.7%) 77 (19.8%) ECOG pe o mance s a us (n =364) 0, n (%) 30 (25.4%) 105 (42.7%) 135 (37.1%) 1, n (%) 65 (55.1%) 125 (50.8%) 190 (52.2%) 2, n (%) 17 (14.4%) 13 (5.3%) 30 (8.2%) 3, n (%) 5 (4.2%) 3 (1.2%) 8 (2.2%) 4, n (%) 1 (0.8%) 0 (0.0%) 1 (0.3%) Me as asis (n =341), n (%) 80 (64.5%) 173 (69.8%) 253 (68%) Tumo si e (n =425) Gynecologic, n (%) 24 (18.8%) 19 (6.4%) 43 (10.1%) Lung, n (%) 37 (28.9%) 47 (15.8%) 84 (19.8%) Diges i e, n (%) 18 (14.1%) 82 (27.6%) 100 (23.5%) Geni ou ina y, n (%) 11 (8.6%) 17 (5.7%) 28 (6.6%) Lymphoma, n (%) 9 (7%) 49 (16.5%) 58 (13.6%) O he si es, n (%) 29 (22.7%) 83 (27.9%) 112 (26.4%) Abb e ia ions: VTE: enous h omboembolism; SD: s anda d de ia ion; HDL: high-densi y lipop o ein; LDL: low-densi y lipop o ein; ECOG: Eas e n Coope a i e Oncology G oup. Cance s 2020,12, 75 6 o 12 Table 2. Di e ences in he Pemb-QOL, EORTC QLQ-C30 unc ional and symp oms scales, EQ-5D-3L, and VEINES scale sco es be ween cases and con ols. Pemb-QOL 1Cases (Cance wi h VTE) Con ols (Cance wi hou VTE) Mean Di e ence E ec Size (95% CI) Rela i e E iciency (95% CI) Quali y o li e 44.4 23.0 +21.4 ** 0.99 (0.6; 1.5) 0.93 (0.6; 1.2) F equency o complain s 33.6 21.0 +12.6 ** 0.86 (0.6; 1.4) 0.51 (0.2; 0.8) Ac i i ies daily li ing limi a ions 52.1 29.3 +22.8 ** 1.06 (0.7; 1.7) 0.79 (0.4; 1.1) Wo k- ela ed p oblems 72.9 39.5 +33.4 ** 0.84 (0.5; 1.3) 0.74 (0.4; 1.0) Social limi a ions 37.2 15.5 +21.7 ** 1.47 (0.9; 2.3) 0.78 (0.4; 1.1) In ensi y o complain s 33.9 15.5 +18.4 ** 1.32 (0.9; 2.1) 0.86 (0.5; 1.1) Emo ional complain s 36.4 17.0 +19.4 ** 1.33 (0.9; 2.1) 0.89 (0.6; 1.2) EORTC QLQ-C30 Func ional Scale 2 Cases (Cance wi h VTE) Con ols (Cance wi hou VTE) Mean Di e ence E ec Size (95% CI) Rela i e E iciency (95% CI) Global heal h s a us 47.7 58.4 −10.3 ** 0.95 (0.7; 1.3) −0.42 (−0.6; −0.2) Physical unc ioning 64.4 80.6 −16.2 ** 1.29(0.9; 1.8) −0.70 (−0.9; −0.4) Role unc ioning 53.9 74.7 −20.8 ** 1.25 (0.9; 1.7) −0.65 (−0.9; −0.4) Emo ional unc ioning 67.2 72.3 −5.1 0.94 (0.7; 1.3) −0.2 (−0.04; 0.1) Cogni i e unc ioning 81.7 84.4 −2.7 1.37 * (1.0; 1.9) −0.11 (−0.3; 0.1) Social unc ioning 62.2 74.1 −11.9 ** 1.35 (0.9; 1.8) −0.39 (−0.6; −0.1) EORTC QLQ-C30 symp oms scale 3 Cases (Cance wi h VTE) Con ols (Cance wi hou VTE) Mean Di e ence E ec Size (95% CI) Rela i e E iciency (95% CI) Fa igue 48.4 33.7 +14.7 ** 1.27 (0.9; 1.7) 0.52 (0.3; 0.7) Nausea and omi ing 14.2 11.5 +2.7 0.98 (0.7; 1.3) 0.12 (−0.1;0.3) Pain 36.0 23.0 +13.0 ** 1.48 * (1.0; 2.0) 0.4 (0.2; 0.7) Dyspnea 23.5 13.0 +10.5 ** 1.5 ** (1.1; 2.0) 0.39 (0.2; 0.6) Insomnia 30.1 31.9 −1.8 0.97 (0.7; 1.3) −0.05 (−0.2;0.2) Appe i e loss 25.8 25.3 +0.5 1.0 (0.7; 1.4) 0.01 (−0.2;0.2) Cons ipa ion 26.7 22.1 +4.6 1.25 (0.9; 1.7) 0.1 (−0.1;0.4) Dia hea 15.1 16.5 +1.4 1.21 (0.9; 1.7) −0.05 (−0.3;0.2) Financial di icul ies 23.4 17.8 +5.6 1.35 (0.9; 1.9) 0.2 (−0.03;0.4) EQ-5D-3L 4Cases (Cance wi h VTE) Con ols (Cance wi hou VTE) Mean Di e ence E ec Size (95% CI) Rela i e E iciency (95% CI) Index sco e 0.55 0.77 −0.22 ** 2.06 ** (1.5; 2.8) −0.7 (−0.9; −0.5) VEINES-QOL/Sym 5Cases (Cance wi h VTE) Con ols (Cance wi hou VTE) Mean Di e ence E ec Size (95% CI) Rela i e E iciency (95% CI) VEINES-QOL 42.7 51.7 −9.0 ** 0.82 (0.53; 1.20) 1.0 (0.79; 1.38) VEINES/Sym 43.8 51.4 −7.6 ** 0.80 (0.5–1.2) 0.8 (0.5–1.0) Abb e ia ions: VTE: enous h omboembolism; CI: con idence in e al. * p<0.05; ** p<0.001. 1 Pemb-QOL: Highe sco es e lec a lowe quali y o li e and he minimally clinically impo an di e ence is 15 poin s; 2 EORTC QLQ-C30 unc ional scale: Highe sco es e lec a be e heal h s a us and he minimally impo an di e ence a ies om 6 o 15 poin s; 3 EORTC QLQ-C30 symp oms scale: Highe sco es in he symp oms scale indica e a educ ion in quali y o li e; 4 EQ-5D-3L: Highe sco es e lec a be e heal h s a us and he minimally impo an di e ence on he EQ-5D ques ionnai e o pa ien s wi h malignancies is 0.06 − 0.08 UI; 5 VEINES-QOL/Sym: Highe sco es e lec a be e heal h s a us. Cases and con ols di e ed signi ican ly in e ms o PEmb-QoL esul s, and such di e ence was la ge han he MID wi h ega d o QoL (44.4 e sus 23, espec i ely; mean di e ence: − 21.4) and i e o he six measu ed dimensions. Simila ly, he VEINES-QOL/Sym ques ionnai e showed wo se QoL in cases han in con ols (42.7 e sus 51.7, espec i ely; mean di e ence: − 9), wi h he o me g oup ha ing mo e symp oms (43.8 e sus 51.4, espec i ely; mean di e ence: − 7.6). Figu e 1shows ou sec ions o he iolin plo indica ing di e ences in he median be ween cases and con ols (p<0.05). The e we e also ma ked di e ences in ke nel dis ibu ion. Speci ically, da a om con ols su ounded he median alues o he ou ques ionnai es, whe eas a wide dis ibu ion was obse ed o cases. Cance s 2020,12, 75 7 o 12 Cance s 2020, 12, x FOR PEER REVIEW 7 o 12 Figu e 1. Cases and con ols dis ibu ion o he da a and i s p obabili y densi y in di e en ques ionnai es. Violin plo s. (A) QLQ-c30 Global Heal h S a us, (B) Pemb-QOL, (C) EQ-5D-3L Index, and (D) VEINES QOL. The plo s show he ac ual dis ibu ion o he obse ed alues (do s in cases and iangles in con ols), ul ima ely allowing a ep esen a ion o he sco es used in he s udy. Boxplo s depic s he median (black line inside he box) and he in e qua ile ange ( he edges o he box). The ke nel densi y plo (g ey line) ep esen s he p obabili y densi y unc ion. La ge sec ions o he iolin plo indica e a highe p obabili y o obse a ion a a gi en alue, whe eas hinne sec ions co espond o a lowe p obabili y. 3.2. Subg oup Analysis No signi ican di e ences in e ms o EQ-5D-3L esul s we e ound be ween pa ien s wi h PE e sus DVT. Howe e , he wo g oups di e ed signi ican ly wi h ega d o dyspnea as measu ed by he EORTC QLQ-C30 ques ionnai e, and such di e ence was la ge han he MID (32.7 e sus 15.9; mean diffe ence: −16.8; Table S3). We subsequen ly pe o med an age- and sex-s a i ied analysis o he EORTC QLQ-C30 ques ionnai e in cases and con ols. Rega dless o sex, we ound s a is ically signi ican di e ences la ge han he MID in he g ea majo i y o he unc ioning scales (Table S4). Simila di e ences we e obse ed on he EQ-5D-3L ques ionnai e. As a as he PEmb-QoL ques ionnai e is conce ned, he p esence o PE was ound o a ec QoL (wi h he di e ence being la ge han he MCID) in women bu no in men (49.9 e sus 20.1, espec i ely; mean diffe ence: −29.8). Simila indings we e obse ed wi h ega d o all o he dimensions. Only wo k- ela ed p oblems and he in ensi y o complain s we e ound o be a ec ed in men. In con as , he VEINES-QOL/Sym ques ionnai e showed s a is ically signi ican di e ences in bo h sexes. When QoL was analyzed in ela ion o he cance si e, he unc ioning scales o he EORTC QLQ- C30 ques ionnai e showed s a is ically signi ican di e ences (la ge han he MID) in se e al dimensions among pa ien s wi h gynecologic and diges i e umo s. Pa ien s wi h gynecologic malignancies also showed di e ences in global heal h s a us, physical s a us, ole, and social unc ioning. Wi h ega d o diges i e umo s, signi ican di e ences we e obse ed in physical s a us, Figu e 1. Cases and con ols dis ibu ion o he da a and i s p obabili y densi y in di e en ques ionnai es. Violin plo s. ( A ) QLQ-c30 Global Heal h S a us, ( B ) Pemb-QOL, ( C ) EQ-5D-3L Index, and ( D ) VEINES QOL. The plo s show he ac ual dis ibu ion o he obse ed alues (do s in cases and iangles in con ols), ul ima ely allowing a ep esen a ion o he sco es used in he s udy. Boxplo s depic s he median (black line inside he box) and he in e qua ile ange ( he edges o he box). The ke nel densi y plo (g ey line) ep esen s he p obabili y densi y unc ion. La ge sec ions o he iolin plo indica e a highe p obabili y o obse a ion a a gi en alue, whe eas hinne sec ions co espond o a lowe p obabili y. 3.2. Subg oup Analysis No signi ican di e ences in e ms o EQ-5D-3L esul s we e ound be ween pa ien s wi h PE e sus DVT. Howe e , he wo g oups di e ed signi ican ly wi h ega d o dyspnea as measu ed by he EORTC QLQ-C30 ques ionnai e, and such di e ence was la ge han he MID (32.7 e sus 15.9; mean di e ence: −16.8; Table S3). We subsequen ly pe o med an age- and sex-s a i ied analysis o he EORTC QLQ-C30 ques ionnai e in cases and con ols. Rega dless o sex, we ound s a is ically signi ican di e ences la ge han he MID in he g ea majo i y o he unc ioning scales (Table S4). Simila di e ences we e obse ed on he EQ-5D-3L ques ionnai e. As a as he PEmb-QoL ques ionnai e is conce ned, he p esence o PE was ound o a ec QoL (wi h he di e ence being la ge han he MCID) in women bu no in men (49.9 e sus 20.1, espec i ely; mean di e ence: − 29.8). Simila indings we e obse ed wi h ega d o all o he dimensions. Only wo k- ela ed p oblems and he in ensi y o complain s we e ound o be a ec ed in men. In con as , he VEINES-QOL/Sym ques ionnai e showed s a is ically signi ican di e ences in bo h sexes. When QoL was analyzed in ela ion o he cance si e, he unc ioning scales o he EORTC QLQ-C30 ques ionnai e showed s a is ically signi ican di e ences (la ge han he MID) in se e al dimensions among pa ien s wi h gynecologic and diges i e umo s. Pa ien s wi h gynecologic malignancies also Cance s 2020,12, 75 8 o 12 showed di e ences in global heal h s a us, physical s a us, ole, and social unc ioning. Wi h ega d o diges i e umo s, signi ican di e ences we e obse ed in physical s a us, ole, emo ional, and cogni i e unc ioning (Table S5). An analysis o symp oms on he EORTC QLQ-C30 ques ionnai e is p o ided in Table S6. The EQ-5D-3L ques ionnai e yielded s a is ically signi ican di e ences (la ge han he MID) o all umo si es, he only excep ion being lung cance (Table S7). In he subg oup o pa ien s wi h DVT, he VEINES-QOL/Sym ques ionnai e iden i ied s a is ically signi ican di e ences in bo h QoL and symp oms o pa ien s wi h diges i e and pulmona y umo s (Table S8). The esul s on he PEmb-QoL ques ionnai e we e also ound o di e acco ding o he umo si e (Table S9). 4. Discussion The p esen case-con ol analysis demons a es a signi ican de imen al impac o acu e symp oma ic VTE on QoL o pa ien s wi h malignancies, wi h a wo se global heal h s a us being de ec ed by all o he ou ques ionnai es used in ou s udy. The e we e di e ences la ge han he MID on he EQ-5D-3L and he EORTC QLQ-C30 ques ionnai es and g ea e han he MCID on he PEmb-QoL ques ionnai e. Mo eo e , a s a is ically signi ican wo se QoL was iden i ied on he VEINES-QOL/Sym ques ionnai e. Using he EORTC QLQ-C30 ques ionnai e, we simila ly showed ha acu e symp oma ic VTE is associa ed wi h lowe physical unc ioning, ole unc ioning, social unc ioning, as well as highe a igue, pain, and dyspnea. A de imen al impac was also obse ed on i e o he six dimensions o he PEmb-QoL ques ionnai e. Ou indings ha e p ac ical implica ions. Owing o he nega i e impac o h ombosis on he quali y o li e o pa ien s wi h malignancies, heal hca e pe sonnel should be awa e o his aspec and pay adequa e a en ion o i s de ec ion. In addi ion, ou da a may pa e he way o u u e esea ch aimed a assessing he impac on quali y o li e o ea men s and in e en ions implemen ed in pa ien s wi h cance -associa ed h ombosis. Acco ding o he Wo ld Heal h O ganiza ion, QoL should be conside ed as a mul idimensional concep [ 28 ]. Gene ic QoL ques ionnai es allow compa ing o di e en diseases o p ocesses, whe eas disease-speci ic ques ionnai es can se e as mo e sensi i e ools o analyzing he epe cussions o a gi en disease on he pa ien . Recen yea s ha e wi nessed a moun ing in e es in QoL as a heal hca e ou come measu e—wi h inc easingly mo e s udies ocusing no only on he quan i y bu also on he quali y o li es li ed [29]. In a s udy conduc ed in 359 pa ien s wi h DVT, Kahn e al. [ 13 ] in es iga ed QoL by adminis e ing he 36-I em Sho -Fo m Heal h Su ey (SF-36) and he VEINES QOL/Sym ques ionnai es a baseline and a wo di e en ollow-up isi s (a 1 and 4 mon hs). The esul s o he VEINES QOL/Sym ques ionnai e demons a ed a sligh ly highe QoL in hei sample compa ed wi h ou s udy (50 e sus 42.7, espec i ely). This di e ence may be explained by he ac ha only 12.5% o hei s udy pa ien s had cance [ 13 ]. Ta oly e al. [ 14 ] pe o med a c oss-sec ional s udy o QoL in 213 pa ien s wi h PE—wi h hei esul s showing a highe EQ-5D index sco e han ha obse ed in ou s udy (0.8 e sus 0.55, espec i ely). Such di e ence may be a ibu ed o he ac ha only 7% o hei s udy pa icipan s had a diagnosis o cance . In addi ion, ques ionnai es we e adminis e ed a e 4 mon hs and 10 yea s om he index PE e en [ 14 ]. The p ospec i e, obse a ional, in e na ional PREFER s udy in es iga ed he QoL o 1399 pa ien s wi h PE using he EQ-5D-5L ques ionnai e‚—wi h a epo ed sco e o 0.71 ± 0.27 a he ime o e en [ 30 ]. Only 120 pa ien s (8.6%) in his s udy had a diagnosis o cance and disease-speci ic QoL ques ionnai es we e no u ilized. The QUAVITEC s udy was a p ospec i e, longi udinal s udy o pa ien s wi h cance and VTE [ 31 ] who we e adminis e ed h ee ques ionnai es on QoL (SF-36, EORTC QLQ-C30, and VEINES-QOL) a baseline and a wo ollow-up isi s (3 and 6 mon hs). Al hough a be e QoL was epo ed a 6 mon hs a e he index VTE e en , hese esul s should be in e p e ed cau iously because only 49% o he s udy pa ien s unde wen he 6-mon h assessmen . No ably, he global heal h s a us/QoL sco e on he EORTC QLQ-C30 ques ionnai e was simila o ha obse ed in ou cu en in es iga ion (47 e sus 47.7, espec i ely). A sub-analysis o he CATCH ial has been published in 2008 [ 32 ]. The s udy in es iga ed he u ili y o LMWH inzapa in in p e en ing ecu en VTE in pa ien s wi h di e en ypes o cance and he EQ-5D ques ionnai e was Cance s 2020,12, 75 9 o 12 adminis e ed o he pa icipan s. The au ho s ound ha ecu en VTE had a signi ican impac on EQ-5D sco es (dec ease: − 0.075). The s eng hs o his s udy included he la ge sample size (n =883) and he epea ed mon hly measu es o quali y o li e o 7 mon hs. Howe e , his esea ch also had some inhe en ca ea s, including he use o a gene ic—and no disease-speci ic—ques ionnai e and he compa ison wi h a p ede ined pa ien p o ile (male, om Wes e n Eu ope, wi hou dis an me as ases, wi h symp oma ic DVT as he quali ying e en , and an ECOG pe o mance s a us o 1 a baseline). Da a ob ained om quali y o li e ques ionnai es p o ide clinically ele an and ep oducible in o ma ion wi h espec o di e en pa ien dimensions. These esul s may be also complemen ed wi h quali a i e esea ch wo k. In his ega d, a p e ious s udy conduc ed semi-s uc u ed in e iews in 14 pa ien s wi h cance -associa ed h ombosis [ 33 ]. The esul s indica ed no only ha VTE had a majo ad e se impac on hei li e bu also ha h ombosis was conside ed a dis inc en i y— a he han a pa —o hei cance illness. The ollowing h ee a eas we e ound o be a ec ed by VTE: (1) symp om bu den; (2) impac in he con ex o hei cance jou ney; (3) impac on hei ac i i ies o daily li ing. Ou s udy has se e al s eng hs. Fi s , we speci ically ocused on he impac o acu e symp oma ic VTE on QoL in pa ien s wi h cance using di e en ques ionnai es. This app oach allowed us o compa e ou indings wi h hose ob ained in o he diseases (owing o he use o he gene ic EQ-5D-3L ques ionnai e), in o he cance -associa ed complica ions (owing o he use o he EORTC QLQ-C30 ques ionnai e), and in o he clinical popula ions wi h VTE (owing o he use o he PEmb-QoL and VEINES-QOL ques ionnai es). Second, ou case-con ol design allowed us ob aining di ec compa isons o QoL, wi hou eso ing o his o ical coho s cha ac e ized by di e en demog aphic and clinical cha ac e is ics. Thi d, he compa a i e analysis o QoL conduc ed in ou s udy ook in o accoun ei he MID o MCID. We we e he e o e able o iden i y clinically ele an di e ences ha we e no me ely s a is ically signi ican . Howe e , ou indings need o be in e p e ed in he con ex o some limi a ions. Fi s , al hough he design o ou wo k was a case-con ol s udy, he p ospec i e and mul icen e na u e o ou case-con ol s udy did no allow us ob aining a pe ec ma ching o all a iables ha may po en ially a ec quali y o li e. Fo example, umo loca ion was no well balanced be ween cases and con ols. In any case, h ombosis was ound o ha e a nega i e impac on quali y o li e ega dless o umo loca ion. In addi ion, mo e han hal o all cases (54.5%) and con ols (58.1%) we e included wi hin 6 mon hs om cance diagnosis. Also, he me as asis a e did no show signi ican in e g oup di e ences. Mo eo e , he e we e o he a iables ha could a ec o QoL ha we e no included in ou s udy (i.e., chemo he apy use, episodes o neu openic e e , in ec ions, ecen hospi aliza ions, i pa ien s ecei ed cu a i e o pallia i e ea men o 12-mon h su i al p obabili y in bo h g oups). Second, he numbe o pa icipan s was no su icien ly la ge o de ec s a is ically signi ican di e ences in ce ain ques ionnai e dimensions o speci ic subg oups. This ca ea despi e ha p ede e mined sample size was su icien ly la ge o demons a e an impac o acu e symp oma ic VTE on QoL o pa ien s wi h malignancies—a hypo hesis ha was ul ima ely con i med. Thi d, we did no pe o m se ial assessmen s o QoL in ou sample. Al hough his me hodological aspec may be essen ial in pa ien s wi h VTE and no malignancies, i s impo ance is less pa amoun in he oncology se ing. Acco dingly, he dismal p ognosis o pa ien s wi h me as a ic cance may lead o a bias simila o ha occu ing in he QUAVITEC s udy, which showed an imp o ed QoL a a 6-mon h ollow-up, albei a he expenses o a limi ed numbe o esponde s (less han 50% compa ed wi h baseline) [31]. 5. Conclusions In summa y, he esul s o ou s udy demons a e ha acu e symp oma ic VTE has an ad e se impac on he QoL o pa ien s wi h malignancies. Clinicians who ea cance -associa ed h ombosis should be awa e ha his e en is no me ely a complica ion bu has a b oade impac on he pa ien ’s quali y o li e, ul ima ely equi ing a comp ehensi e clinical managemen .